BMS Orencia, Lilly Forteo Among Japanese Approval Recommendations
This article was originally published in PharmAsia News
The First Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare April 23 recommended Bristol-Myers Squibb's Orencia (abatacept) and Eli Lilly's Forteo (teriparatide) for approval; Takeda, Boehringer Ingelheim, Nippon Shinyaku and Genyzme also saw approvals
You may also be interested in...
The First Subcommittee on New Drugs at Japan's Ministry of Health June 3 recommended six drugs for approval, including Wyeth/Pfizer's Viviant (bazedoxifene), clearing a hurdle for the merged companies' lead selective estrogen reuptake modulator for postmenopausal osteoporosis in Japan's crowded market
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).